ClinVar Miner

Submissions for variant NM_000536.4(RAG2):c.193G>T (p.Asp65Tyr)

dbSNP: rs909264507
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen Severe Combined Immunodeficiency Variant Curation Expert Panel, ClinGen RCV003403136 SCV004102792 likely pathogenic Recombinase activating gene 2 deficiency 2023-11-14 reviewed by expert panel curation The NM_000536.4:c.193G>T variant in RAG2 is a missense variant predicted to cause substitution of aspartic acid by tyrosine at amino acid 65 (p.Asp74Tyr). The variant has been reported in one individual with SCID. The individual was homozygous of this variant (PM3_Supporting, PMID 21624848). The individual had a T-B-NK+ lymphocyte profile and showed reduced T-cell proliferation under PHA stimulation, which supports a diagnosis of leaky/atypical SCID (PP4, PMID 21624848). The highest population minor allele frequency of this variant in gnomAD v2.1.1 is 0.000008791 (1/113758 alleles) in the European (non-Finnish) population, which is lower than the SCID-VCEP threshold (<0.0000588) for PM2_Supporting. No homozygous individual has been observed in the gnomAD v2.1.1 (PM2_Supporting). This variant resides within the core domain (amino acids 1-383) of RAG2, defined as a critical functional domain by the ClinGen SCID VCEP. (PM1_Supporting). An in vitro recombination activity assay shows that the relevant activity of the p.D65Y variant compared to wildtype RAG2 is 6.8%, which is below the threshold (<25%) established by the SCID VCEP for PS3_Moderate (PS3_Moderate, PMID 29772310). In summary, this variant meets the criteria to be classified as likely pathogenic for autosomal recessive recombinase activating gene 2 deficiency based on the ACMG/AMP criteria applied, as specified by the ClinGen SCID VCEP. Criteria applied: PP4, PM3_Supporting, PM2_Supporting, PM1_Supporting, and PS3_Moderate (VCEP specifications version 1.0).
GeneDx RCV000489480 SCV000577637 pathogenic not provided 2020-01-20 criteria provided, single submitter clinical testing Published functional studies demonstrate a damaging effect with a recombination activity of 6.8% of WT hRAG2(Tirosh 2018); Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 21624848, 29772310)
Pediatric Immunology Service, The Chaim Sheba Medical Center at Tel HaShomer RCV000681576 SCV000693924 likely pathogenic Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-positive; Recombinase activating gene 2 deficiency; Inborn error of immunity 2018-03-06 criteria provided, single submitter research
Fulgent Genetics, Fulgent Genetics RCV002496885 SCV002802552 likely pathogenic Combined immunodeficiency with skin granulomas; Histiocytic medullary reticulosis; Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-positive 2021-11-12 criteria provided, single submitter clinical testing
Invitae RCV002526041 SCV003439691 uncertain significance Combined immunodeficiency with skin granulomas; Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-positive 2021-12-28 criteria provided, single submitter clinical testing This sequence change replaces aspartic acid, which is acidic and polar, with tyrosine, which is neutral and polar, at codon 65 of the RAG2 protein (p.Asp65Tyr). This variant is present in population databases (no rsID available, gnomAD 0.0009%). This missense change has been observed in individual(s) with severe combined immunodeficiency (PMID: 21624848). ClinVar contains an entry for this variant (Variation ID: 427020). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt RAG2 protein function. Experimental studies have shown that this missense change affects RAG2 function (PMID: 29772310). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV003226307 SCV003922723 likely pathogenic Severe combined immunodeficiency disease 2023-03-14 criteria provided, single submitter clinical testing Variant summary: RAG2 c.193G>T (p.Asp65Tyr) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 251474 control chromosomes (gnomAD). c.193G>T has been reported in the literature in an individual homozygous for the variant affected with Severe Combined Immunodeficiency (Dalal_2011). These data indicate that the variant may be associated with disease. At least one publication reported experimental evidence evaluating an impact on protein function, and demonstrated severely decreased recombinase activity (Tirosh_2019). Four submitters have provided clinical-significance assessments for this variant to ClinVar after 2014, and classified the variant as pathogenic (n=1), likely pathogenic (n=2), or uncertain significance (n=1). Based on the evidence outlined above, the variant was classified as likely pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.